PMID- 38091192
OWN - NLM
STAT- MEDLINE
DCOM- 20240111
LR  - 20240304
IS  - 1708-0428 (Electronic)
IS  - 0960-8923 (Linking)
VI  - 34
IP  - 1
DP  - 2024 Jan
TI  - Effect of Swallow Balloon Therapy with the Combination of Semaglutide Oral 
      Formulation: a Randomised Double-Blind Single-Centre Study.
PG  - 198-205
LID - 10.1007/s11695-023-06975-8 [doi]
AB  - BACKGROUND: Obesity is a significant public health issue; new therapies and 
      pharmaceutical approaches to weight management are needed. OBJECTIVE: This study 
      assesses weight reduction efficacy in the novel swallow balloon procedure and 
      semaglutide, both promising non-surgical and pharmaceutical options, addressing 
      obesity's critical public health challenge. METHODS: This was a 
      computer-generated, blocked randomisation, double-blind, single-centre study. 
      Fifty-seven participants were assigned to swallow balloon therapy group I (with 
      semaglutide), and 58 were assigned to swallow balloon therapy group II (without 
      semaglutide). All treatment doses were orally administered once daily (3 mg for 
      the 1(st) month, 7 mg for the 2(nd) month, and 14 mg for the 3(rd) and 4(th) 
      months after the placement of the swallow balloon). All the data were 
      statistically analysed. RESULTS: The groups were highly well-matched. The %TWL in 
      group I was 7.9%, 12.5%, 15.2%, and 17.6% and in group II was 6.1%, 10.5%, 12.8%, 
      and 13.7% at 1, 2, 3, and 4 months, respectively. The most common adverse events 
      (AEs) were nausea and vomiting, observed within the week. The resolution of T2DM, 
      HTN, and OSA was 64.7% vs 55.5%, 64.3% vs 58.8%, and 72.0 vs 57.8% in groups I vs 
      II, respectively. QoL significantly improved 4 months postoperatively in both 
      groups. No major late complications occurred in either of the groups. CONCLUSION: 
      The study supports the efficacy of swallow balloon therapy combined with 
      semaglutide oral formulation in promoting weight loss and improving comorbid 
      conditions. The findings highlight the potential of this combined approach in 
      managing obesity and its associated health issues.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Mathur, Winni
AU  - Mathur W
AD  - Mohak Bariatrics and Robotics Center, Sri Aurobindo University, Indore-Ujjain 
      Highway, Indore, Madhya Pradesh, 453555, India.
FAU - Kosta, Susmit
AU  - Kosta S
AD  - Mohak Bariatrics and Robotics Center, Sri Aurobindo University, Indore-Ujjain 
      Highway, Indore, Madhya Pradesh, 453555, India.
FAU - Reddy, Manoj
AU  - Reddy M
AD  - Mohak Bariatrics and Robotics Center, Sri Aurobindo University, Indore-Ujjain 
      Highway, Indore, Madhya Pradesh, 453555, India.
FAU - Neto, Manoel Galvao
AU  - Neto MG
AD  - Mohak Bariatrics and Robotics Center, Sri Aurobindo University, Indore-Ujjain 
      Highway, Indore, Madhya Pradesh, 453555, India.
FAU - Bhandari, Mohit
AU  - Bhandari M
AUID- ORCID: 0000-0001-9608-4808
AD  - Mohak Bariatrics and Robotics Center, Sri Aurobindo University, Indore-Ujjain 
      Highway, Indore, Madhya Pradesh, 453555, India. drmohitbhandari@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20231213
PL  - United States
TA  - Obes Surg
JT  - Obesity surgery
JID - 9106714
RN  - 0 (Hypoglycemic Agents)
RN  - 53AXN4NNHX (semaglutide)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Double-Blind Method
MH  - *Hypoglycemic Agents/therapeutic use
MH  - *Obesity, Morbid/drug therapy/surgery
MH  - Quality of Life
MH  - Treatment Outcome
MH  - Weight Loss
OTO - NOTNLM
OT  - Non-surgical approach
OT  - Obesity
OT  - Semaglutide
OT  - Swallow balloon
OT  - Weight loss
EDAT- 2023/12/13 18:42
MHDA- 2024/01/11 07:43
CRDT- 2023/12/13 13:33
PHST- 2023/10/10 00:00 [received]
PHST- 2023/11/26 00:00 [accepted]
PHST- 2023/11/15 00:00 [revised]
PHST- 2024/01/11 07:43 [medline]
PHST- 2023/12/13 18:42 [pubmed]
PHST- 2023/12/13 13:33 [entrez]
AID - 10.1007/s11695-023-06975-8 [pii]
AID - 10.1007/s11695-023-06975-8 [doi]
PST - ppublish
SO  - Obes Surg. 2024 Jan;34(1):198-205. doi: 10.1007/s11695-023-06975-8. Epub 2023 Dec 
      13.